The entanglement of extracellular matrix molecules and immune checkpoint inhibitors in cancer: a systematic review of the literature

Fejza, Albina; Carobolante, Greta; Poletto, Evelina; Camicia, Lucrezia; Schinello, Giorgia; Di Siena, Emanuele; Ricci, Giuseppe; Mongiat, Maurizio; Andreuzzi, Eva

doi:10.3389/fimmu.2023.1270981

Cited by 3 publications

(1 citation statement)

References 171 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 Instead of vasculature, remodeling the extracellular matrix (ECM) is another method to improve immune infiltration. 66 The dense ECM can also inhibit oxygen flow, preventing the successful ROS generation PDT relies on. 67 To execute such ECM remodeling, microneedle patches were recently formulated with hyaluronidases (HAases) to degrade HA in the TME/ECM.…”

Section: Co-delivery Icd-inducing Pitmentioning

confidence: 99%

The fusion of light and immunity: Advancements in photoimmunotherapy for melanoma

Volety,

Shirley,

Chhabra

et al. 2024

Photochem & Photobiology

View full text Add to dashboard Cite

Metastatic melanoma is an aggressive skin cancer with high mortality and recurrence rates. Despite the clinical success of recent immunotherapy approaches, prevailing resistance rates necessitate the continued development of novel therapeutic options. Photoimmunotherapy (PIT) is emerging as a promising immunotherapy strategy that uses photodynamic therapy (PDT) to unleash systemic immune responses against tumor sites while maintaining the superior tumor‐specificity and minimally invasive nature of traditional PDT. In this review, we discuss recent advances in PIT and strategies for the management of melanoma using PIT. PIT can strongly induce immunogenic cell death, inviting the concomitant application of immune checkpoint blockade or adoptive cell therapies. PIT can also be leveraged to selectively remove the suppressive immune populations associated with immunotherapy resistance. The modular nature of PIT therapy design combined with the potential for patient‐specific antigen selection or drug co‐delivery makes PIT an alluring option for future personalized melanoma care.

show abstract

Section: Co-delivery Icd-inducing Pitmentioning

confidence: 99%

The fusion of light and immunity: Advancements in photoimmunotherapy for melanoma

Volety,

Shirley,

Chhabra

et al. 2024

Photochem & Photobiology

View full text Add to dashboard Cite

show abstract

Proteoglycans of basement membranes: Crucial controllers of angiogenesis, neurogenesis, and autophagy

Mongiat,

Pascal,

Poletto

et al. 2024

Proteoglycan Research

View full text Add to dashboard Cite

Antiangiogenic therapy is an established method for the treatment of several cancers and vascular‐related diseases. Most of the agents employed target the vascular endothelial growth factor A, the major cytokine stimulating angiogenesis. However, the efficacy of these treatments is limited by the onset of drug resistance. Therefore, it is of fundamental importance to better understand the mechanisms that regulate angiogenesis and the microenvironmental cues that play significant role and influence patient treatment and outcome. In this context, here we review the importance of the three basement membrane (BM) heparan sulfate proteoglycans (HSPGs), namely perlecan, agrin, and collagen XVIII. These HSPGs are abundantly expressed in the vasculature and, due to their complex molecular architecture, they interact with multiple endothelial cell receptors, deeply affecting their function. Under normal conditions, these proteoglycans exert proangiogenic functions. However, in pathological conditions such as cancer and inflammation, extracellular matrix remodeling leads to the degradation of these large precursor molecules and the liberation of bioactive processed fragments displaying potent angiostatic activity. These unexpected functions have been demonstrated for the C‐terminal fragments of perlecan and collagen XVIII, endorepellin, and endostatin. These bioactive fragments can also induce autophagy in vascular endothelial cells which contributes to angiostasis. Overall, BM proteoglycans deeply affect angiogenesis counterbalancing proangiogenic signals during tumor progression and represent possible means to develop new prognostic biomarkers and novel therapeutic approaches for the treatment of solid tumors.

show abstract

TET1 was correlated with prognosis and immunity in glioma: analysis of the TET protein family

Li,

Zhou,

Feng

et al. 2024

Preprint

View full text Add to dashboard Cite

Background The ten-eleven translocation (TET) protein family, which includes TET1, TET2, and TET3, plays a crucial role in tumorigenesis by either activating or repressing the transcription of target genes in different cellular processes. However, the role of TET protein family in glioma is currently unclear. Methods We analyzed the expression level of TET protein family in pan-cancer and their correlation with prognosis using the GTEx and TCGA databases. We also acquired both genomic sequencing profiles and patients’ clinical details for healthy brain samples and glioma specimens from the databases of TCGA and CGGA. The differential expression of TET protein family in glioma and their correlation with prognosis were analyzed. The results have been subsequently confirmed using immunohistochemistry techniques. To evaluate risk elements associated with the occurrence and progression of glioma, we employed both univariate and multivariate Cox regression analyses. Furthermore, we performed analyses of functional enrichment, specifically focusing on genes related to TET1, using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). To evaluate the correlation between immune cell infiltration level and TET1 expression in glioma, we employed the single-sample GSEA (ssGSEA) approach. Moreover, we investigated the association between TET1 and drug sensitivity. Results Expression levels of TET protein family were markedly increased in glioma relative to normal tissue. The increase is more significant in IDH-mutant glioma compared to IDH-wildtype glioma, as confirmed by immunohistochemical analysis. TET1 expression levels correlate with tumor grades in glioma, regardless of IDH mutation status, but TET2 and TET3 expressions do not show a similar relationship. TET1 was also found to be an independent prognostic factor for glioma by univariate and multifactorial Cox analysis. Research on biological processes has revealed a strong correlation between TET1 and immunity. Additionally, the expression of TET1 showed a correlation with the presence of macrophages, neutrophils, eosinophils, T cells, and Tcm in tumor infiltration. Further study also revealed that TET1 is linked to drug sensitivity. Conclusion TET1, rather than TET2 and TET3, is a critical prognostic biomarker that is associated with the progression, prognosis, and immunity in glioma.

show abstract

The entanglement of extracellular matrix molecules and immune checkpoint inhibitors in cancer: a systematic review of the literature

Cited by 3 publications

References 171 publications

The fusion of light and immunity: Advancements in photoimmunotherapy for melanoma

The fusion of light and immunity: Advancements in photoimmunotherapy for melanoma

Proteoglycans of basement membranes: Crucial controllers of angiogenesis, neurogenesis, and autophagy

TET1 was correlated with prognosis and immunity in glioma: analysis of the TET protein family

Contact Info

Product

Resources

About